Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened

Traws Pharma, Inc. (NASDAQ:TRAW)’s stock price was down 11.2% during trading on Monday . The company traded as low as $1.41 and last traded at $1.43. Approximately 240,143 shares changed hands during trading, an increase of 29% from the average daily volume of 186,351 shares. The stock had previously closed at $1.61.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TRAW shares. Wall Street Zen cut shares of Traws Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a report on Friday, January 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a report on Monday, December 22nd. HC Wainwright assumed coverage on Traws Pharma in a research report on Wednesday, December 3rd. They set a “buy” rating and a $8.00 target price for the company. Finally, Zacks Research upgraded Traws Pharma to a “hold” rating in a research report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Trading Down 11.2%

The firm has a market capitalization of $11.43 million, a price-to-earnings ratio of 0.01 and a beta of 1.78. The firm has a fifty day moving average price of $1.74 and a 200 day moving average price of $1.98.

Institutional Trading of Traws Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Squadron Capital Management LLC bought a new position in shares of Traws Pharma in the fourth quarter valued at about $806,000. Ikarian Capital LLC raised its stake in shares of Traws Pharma by 2,280.0% in the fourth quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after acquiring an additional 649,649 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Traws Pharma during the fourth quarter valued at approximately $220,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Traws Pharma during the fourth quarter valued at approximately $175,000. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.